13F Pro quality score
Rank #2,876 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Lexaria Bioscience Corp. (LEXX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEXX at 9.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,876 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2026), Lexaria Bioscience Corp. reports net income of $-2.0M, free cash flow of $-1.6M. LEXX trades on the Nasdaq exchange and files with the SEC under CIK 1348362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexaria Bioscience Corp. directly from SEC EDGAR.